Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Christelle Ferra,María José Terol,Juan Marquet Palomanes,Angel Ramírez Payer,Carol Moreno,Santiago Osorio,Fátima De la Cruz,Jose A. Garcia-Marco,Macarena Ortiz,Eduardo Rios Herranz,Laura Magnano,Sandra Iraheta,Jose Manuel Puerta,Javier de la Serna, Alicia Smucler,Jose Maria Arguiñano,Javier Loscertales,Begoña Muiña,Rubén Fernández,Tomas García

Blood（2022）

引用 1|浏览18

暂无评分

摘要

Introduction: The BCL-2 inhibitor venetoclax (Ven) has been approved on monotherapy or combined with rituximab in relapsed/refractory CLL patients (pts) and combined with obinutuzumab in previously untreated CLL pts. However, evidence from clinical trials can be difficult to generalize to real-world patient populations. The VENARES study assesses the real-world use of Ven following approval to inform of subpopulations underrepresented in clinical trials.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要